Earnings summaries and quarterly performance for Septerna.
Executive leadership at Septerna.
JF
Jeffrey Finer
Detailed
Chief Executive Officer
CEO
DL
Daniel Long
Detailed
Senior Vice President, Drug Discovery
GL
Gil Labrucherie
Detailed
Chief Financial Officer
JK
Jae Kim
Detailed
Chief Medical Officer
LB
Liz Bhatt
Detailed
President and Chief Operating Officer
SS
Samira Shaikhly
Detailed
Chief People Officer
UK
Uwe Klein
Detailed
Senior Vice President, Biological Sciences
Board of directors at Septerna.
Research analysts covering Septerna.
Recent press releases and 8-K filings for SEPN.
Septerna Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
SEPN
New Projects/Investments
Guidance Update
- Septerna, focused on G-Protein Coupled Receptors (GPCRs) and its Native Complex Platform, completed its IPO in October 2024 and a deal with Novo last summer, providing a cash runway into at least 2029.
- The lead program, SCP479 for hypoparathyroidism, is expected to enter Phase 1 trials in the first half of 2026, with top-line results anticipated later in 2026 or early 2027.
- The second lead program, SCP631 for mast cell diseases, is in a Phase 1 trial, and data is expected to be shared in March 2026.
- Septerna also has earlier-stage programs, including a TSH receptor negative allosteric modulator for Graves' disease and thyroid eye disease, and an incretin receptor agonist program that is part of a collaboration with Novo Nordisk, where Novo covers all R&D costs.
Jan 13, 2026, 11:45 PM
Septerna Updates on Pipeline and Financial Position at J.P. Morgan Healthcare Conference
SEPN
New Projects/Investments
- Septerna completed its IPO in October 2024 and a deal with Novo Nordisk in summer 2025, providing a strong cash runway into at least 2029.
- The company's lead program, SCP479, for hypoparathyroidism, is expected to enter Phase 1 trials in the first half of 2026, with top-line results anticipated late 2026 or early 2027.
- Phase 1 data for SCP631, targeting mast cell diseases, is expected to be shared in March 2026.
- Septerna's collaboration with Novo Nordisk, signed in May 2025 and closed in July 2025, covers three specific receptors and two undisclosed targets, with Novo Nordisk covering all R&D costs going forward.
Jan 13, 2026, 11:45 PM
Septerna Provides Update on Pipeline and Financial Position
SEPN
New Projects/Investments
M&A
Guidance Update
- Septerna is well-capitalized with a cash runway into at least 2029, following its October 2024 IPO and a deal with Novo last summer.
- The company's lead program, SEP-479 for hypoparathyroidism, is set to enter Phase I trials in the first half of 2026, with top-line results anticipated later in 2026 or early 2027.
- Another key program, SEP-631 for mast cell diseases, is nearing completion of its Phase I trial, and data will be shared in March 2026.
- Septerna established a strategic collaboration with Novo Nordisk in May 2025, which includes multiple incretin receptors and undisclosed targets, with Novo covering all R&D costs.
Jan 13, 2026, 11:45 PM
Septerna, Inc. Provides Program Updates and Financial Outlook at J.P. Morgan Healthcare Conference
SEPN
New Projects/Investments
Product Launch
Guidance Update
- Septerna anticipates initiating a Phase 1 clinical trial for SEP-479 (PTH1R Agonist for hypoparathyroidism) in the first half of 2026, with topline data expected in late 2026 or early 2027.
- The company expects to present topline Phase 1 SAD/MAD results for SEP-631 (MRGPRX2 NAM for mast cell-driven diseases) at the AAAAI Annual Meeting in March 2026.
- Septerna has a collaboration with Novo Nordisk for oral small molecules targeting metabolic diseases, which included a $195 million upfront payment received in July 2025 and potential milestones of approximately $500 million per program.
- The company projects its cash runway will support operating plans at least into 2029.
Jan 12, 2026, 1:30 PM
Septerna Provides Clinical Pipeline Updates and Financial Outlook
SEPN
New Projects/Investments
Guidance Update
- Septerna, focused on G protein-coupled receptors (GPCRs), provided updates on its portfolio, including SEP-479 for hyperparathyroidism, SEP-631 for mast cell-driven diseases, a TSHR program for Graves' disease, and an incretin receptor agonist program in collaboration with Novo Nordisk.
- The company's lead candidate, SEP-479, a second-generation PTH1 receptor agonist, is projected to enter the clinic in the first half of next year (2026) after preclinical data showed a projected human half-life of 40-80 hours and an 80% reduction in endogenous PTH levels in a monkey study.
- SEP-631, an MRGPRX2 negative allosteric modulator, is currently in Phase I, with data from its SAD-MAD study, including an Icatibant challenge, anticipated in the first half of next year (2026).
- Septerna is well capitalized with cash runway into at least 2029.
Dec 2, 2025, 3:25 PM
Septerna Provides Updates on Clinical Programs and Financial Runway
SEPN
New Projects/Investments
Guidance Update
- Septerna is well capitalized with a cash runway into at least 2029.
- The company's second-generation PTH1 receptor agonist, SEP-479, for hyperparathyroidism, is structurally unrelated to a discontinued prior candidate and is projected to have a 40-80 hour human half-life. It is expected to enter the clinic in the first half of next year (2026).
- The MRGPRX2 negative allosteric modulator, SEP-631, is currently in Phase 1 for mast cell-driven diseases, with data anticipated in the first half of next year (2026).
- An early-stage TSHR program, a negative allosteric modulator for Graves' disease and thyroid eye disease, has line of sight to a development candidate and could be part of the company's story in 2026.
- Septerna also has an incretin receptor agonist program, which is part of a collaboration with Novo Nordisk announced in May.
Dec 2, 2025, 3:25 PM
Septerna Provides Update on Key Clinical Programs and Pipeline
SEPN
New Projects/Investments
Guidance Update
- Septerna is well-capitalized with a cash runway extending into at least 2029.
- The company's lead candidate, SEP-479, a second-generation PTH1 receptor agonist for hyperparathyroidism, is completing IND-enabling studies and is expected to enter the clinic in the first half of next year (2026).
- SEP-631, an MRGPRX2 negative allosteric modulator for mast cell-driven diseases, is currently in Phase I with data anticipated in the first half of next year (2026).
- An earlier-stage program targeting the thyroid-stimulating hormone receptor (TSHR) for Graves' disease and thyroid eye disease is progressing, with a development candidate expected to be part of the company's story in 2026.
Dec 2, 2025, 3:25 PM
Septerna Provides Updates on Clinical Pipeline and Financial Runway
SEPN
New Projects/Investments
Guidance Update
Product Launch
- Septerna is focused on G protein-coupled receptor (GPCR) drug discovery using its Native Complex Platform.
- The company's lead compound, SEP631, an MRGPRX2 inhibitor for mast cell-driven diseases, is currently in Phase 1, with readouts expected in the first half of next year (2026). Septerna plans to advance SEP631 into a Chronic Spontaneous Urticaria (CSU) trial after Phase 1.
- The second compound, SEP479, a PTH1 receptor agonist for hyperparathyroidism, is anticipated to enter Phase 1 in the first half of next year (2026), with data expected in late 2026 or early 2027. This compound is structurally unrelated to a previous candidate that caused bilirubin increases and has shown no such issues.
- Septerna has a cash runway into at least 2029.
Nov 12, 2025, 9:00 PM
Septerna Updates on Pipeline Progress and Financial Runway
SEPN
New Projects/Investments
Guidance Update
- Septerna, focused on G protein-coupled receptors (GPCRs), reported an operating cash runway into at least 2029.
- The company anticipates SEP479 for hyperparathyroidism to enter the clinic in the first half of next year (2026), and Phase 1 data for SEP631 to be shared in the first half of next year (2026).
- A significant collaboration with Novo Nordisk for an incretin receptor agonist program was announced, including $195 million upfront and coverage of all research and development costs.
- SEP479, a next-generation candidate, is structurally unrelated to the discontinued SEP786 and shows improved pharmaceutical properties, potentially supporting once-daily dosing.
Nov 10, 2025, 9:00 PM
Septerna, Inc. Reports Q3 2025 Financial Results and Business Highlights
SEPN
Earnings
New Projects/Investments
Board Change
- Septerna, Inc. reported a net income of $8.2 million for the third quarter ended September 30, 2025, a significant improvement from a net loss of $20.5 million in the prior year period. Revenue for the quarter was $21.5 million, up from $0.2 million in Q3 2024, primarily due to the Novo Nordisk collaboration.
- As of September 30, 2025, the company held $561.6 million in cash, cash equivalents, and marketable securities, which is projected to fund operations into at least 2029. This cash position includes a $195.0 million upfront payment from Novo Nordisk and a $12.5 million milestone payment from Vertex.
- The company made significant progress in its pipeline, selecting SEP-479 as a next-generation oral PTH1R agonist development candidate, with a Phase 1 clinical trial anticipated in the first half of 2026. A Phase 1 clinical trial for SEP-631 is also ongoing, with initial data expected in the first half of 2026.
- Septerna's global collaboration and license agreement with Novo Nordisk formally commenced in July 2025, initiating joint research and development activities for obesity, type 2 diabetes, and other cardiometabolic diseases. Additionally, Keith Gottesdiener, M.D., was appointed to the Board of Directors in September 2025.
Nov 10, 2025, 1:42 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more